IP Library Granted Patent US 8,715,698
Granted Patent B2
US 8,715,698 · App. 12/678,692 · Granted May 6, 2014

Truncated secretory aspartyl proteinase 2

Inventors: Rinaldo Zurbriggen (Schmitten, CH); Flavia de Bernardis (Rome, IT); Antonio Cassone (Rome, IT); Silvia Rasi (Bern, CH)
Assignees: Pevion Biotech, AG; Istituto Superiore di Sanita
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,698
App. No.
12/678,692
Granted
May 6, 2014
Kind
B2
Abstract

The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.

Claims (14)

1. An isolated polypeptide consisting of

the amino acid sequence of SEQ ID NO:1.

2. A composition comprising the isolate polypeptide of claim 1 .

3. A vaccine composition against Candida albicans comprising:

an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

4. The vaccine composition of claim 3 , further comprising one or more additional components selected from the group consisting of excipients, diluents, adjuvants, and delivery vehicles.

5. A method of eliciting an immune response against Candida albicans in a mammal, wherein the method comprises administering to the mammal a composition comprising the isolated polypeptide of claim 1 .

6. The method of claim 5 , wherein the composition further comprises one or more additional components selected from the group consisting of excipients, diluents, adjuvants, and delivery vehicles.

7. The method of claim 6 , wherein the delivery vehicle is a virosome.

8. The method of claim 7 , wherein the isolated polypeptide is linked to the surface of the virosome.

9. The method of claim 7 , wherein the isolated polypeptide is contained in the lumen of the virosome.

10. The method claim 9 , wherein the isolated polypeptide is both linked to the surface of and contained in the lumen of the virosome.

11. A kit comprising

an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: PEVION BIOTECH LTD.
To: NOVADIGM THERAPEUTICS, INC.
Reel/Frame 033913/0850 →
CHANGE OF NAME Recorded Oct 8, 2014
From: PEVION BIOTECH AG
To: PEVION BIOTECH LTD.
Reel/Frame 033917/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2010
From: ZURBRIGGEN, RINALDO; DE BERNARDIS, FLAVIA; CASSONE, ANTONIO; RASI, SILVIA
To: PEVION BIOTECH AG; ISTITUTO SUPERIORE DI SANITA
Reel/Frame 024638/0706 →
Priority Claims (1)
EP 07018420 · Sep 19, 2007 · regional
Continuity (1)
Related Publication 20100285109A1 · Nov 11, 2010